GlassScriptPhysician profile
Katie Hammond
NPI 1225371909
$1,633.77
in general payments reported to CMS, 2019-2025
34 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2021: $342 · 2022: $211 · 2023: $216 · 2024: $325 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902 · Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.48 |
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $191.60 | 2021 | |
| Novo Nordisk INC | $162.18 | 2019-2025 | Ozempic, Wegovy |
| Abbvie INC. | $150.04 | 2023-2025 | |
| Pfizer INC. | $123.81 | 2019-2025 | |
| Lilly USA, LLC | $107.05 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $88.90 | 2021-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $66.23 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $65.04 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $62.37 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Astrazeneca Pharmaceuticals LP | $51.21 | 2019-2025 | Airsupra, Farxiga |
| Boston Scientific Corporation | $46.02 | 2023-2024 | |
| Antares Pharma, INC. | $39.56 | 2024-2025 | Xyosted |
| Astellas Pharma US INC | $39.18 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $37.85 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $34.67 | 2025 | Auvelity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $34.54 | 2024 | Rexulti |
| Becton, Dickinson and Company | $32.15 | 2022 | |
| Grifols USA, LLC | $24.89 | 2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $23.81 | 2024 | Yupelri |
| Viatris Specialty LLC | $22.05 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $21.02 | 2022 | |
| Clarus Therapeutics INC. | $19.84 | 2021 | |
| Nevro Corp. | $19.03 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.17 | 2025 | |
| Medtronic, INC. | $17.46 | 2022 | |
| Exact Sciences Corporation | $16.23 | 2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $16.20 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.78 | 2025 | Voquezna |
| Amgen INC. | $15.44 | 2025 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2023 | Gattex |
| Insmed, INC. | $14.47 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.36 | 2025 | Caplyta |
| Insulet Corporation | $13.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.